Warm congratulations on the 2011 Sino US Pharmaceutical Industry Summit (2)

Source: on October 18, 2011, speech by sang Guowei, leaders of relevant departments and experts from home and abroad of China Council for the promotion of drugs at the "2011 China US pharmaceutical industry summit" opened on October 18, vice chairman of the Standing Committee of the National People's Congress sang Guowei, leaders of relevant departments and experts from home and abroad successively delivered speeches, warmly congratulating the summit and wishing the meeting a success Guests believe that the summit is an important activity of high-level medical and health exchanges and cooperation between China and the United States, as well as an important measure to implement the central government's work spirit on strengthening non-governmental diplomacy between China and the United States Academician sang Guowei, as the chief technical engineer of major science and technology special project of "major new drug creation" of China, delivered a speech at the opening ceremony, warmly congratulated the convening of the summit, and warmly welcomed the pharma, European and Asian Pharmaceutical friends who came to attend the summit Sang Guowei said that he is very pleased to work with all colleagues in the pharmaceutical industry to study and discuss the topic of intellectual property protection and innovation and development of the pharmaceutical industry The Chinese government attaches great importance to the protection of intellectual property rights At present, China's pharmaceutical industry is facing unprecedented opportunities and challenges Strengthening the protection of pharmaceutical intellectual property is not only an inevitable requirement to protect the legitimate rights and interests of innovators, but also an important legal measure to implement the national policy of supporting the creation of new drugs and encouraging innovation The protection of pharmaceutical intellectual property plays an important role in the strategic security of the whole country, the harmonious development of social economy, the healthy growth of pharmaceutical industry and the general improvement of human health It is hoped that the pharmaceutical industry of China and the United States will carry out more in-depth exchanges and cooperation, and contribute to helping the people of the two countries to obtain better medicines and to the health cause of the two peoples Academician sang Guowei, vice chairman of the Standing Committee of the National People's Congress, delivered a speech to Zhang Wei, vice president of China Council for the promotion of international trade and vice president of China International Chamber of Commerce On behalf of China International Chamber of Commerce, Zhang Wei welcomed and thanked the guests attending the meeting He said that compared with more than 30 years ago, the most important change in China US economic and trade cooperation is that the content of cooperation has expanded from a single commodity trade to various fields of industrial economy At present, the United States is China's second largest export market and main source of investment China is the third largest export market of the United States and the fastest growing export market of the United States With the improvement of the medical security system and the improvement of people's demand for medical services, the Chinese market, which increasingly emphasizes quality, provides a huge business opportunity for the American pharmaceutical enterprises with obvious technological advantages In the process of rapid development, Chinese pharmaceutical enterprises also need to strengthen exchanges and cooperation with American enterprises in technology research and development, enterprise management, intellectual property rights and market development We believe that at present and for a long time to come, the cooperation opportunities of the pharmaceutical industry of China and the United States in the global market are far greater than the competition challenges The two governments and relevant business associations should follow this general direction of development, strengthen exchanges, expand cooperation and resolve disputes through the establishment of various dialogue mechanisms Today, the China International Chamber of Commerce, together with the China Council for the promotion of drugs, the American Chamber of Commerce and the American Association of pharmaceutical research and manufacturers, holds the 2011 Sino US pharmaceutical industry summit Its purpose is to build a platform for communication and cooperation for pharmaceutical enterprises, help Chinese pharmaceutical enterprises actively and steadily move towards internationalization, and better and faster promote the development of Chinese pharmaceutical industry Zhang Wei, vice president of China Council for the promotion of international trade and vice president of China International Chamber of Commerce, addressed mark Elliott, executive director of International Intellectual Property Center of American Chamber of Commerce, rod hunt, senior vice president of PhRMA, and so on Mark Elliott said that the American Chamber of commerce is the largest Chamber of Commerce in the world Our office is just opposite the White House We represent the interests of more than 3 million enterprises and organizations in the United States I am very glad that AmCham has become one of the organizers of this year's China US pharmaceutical industry summit Thank you, vice chairman sang Guowei and Mr weibach, for their foresight and the success of the summit In fact, in today's world, which two countries' bilateral economic and trade relations are the most important? That must be the bilateral economic and trade relations between China and the United States AmCham is committed to maintaining strong growth in bilateral economic and trade relations between the two countries Intellectual property protection is very important It can promote the development of national innovation capacity and ensure that innovation is sustainable and effective No matter in which region, large enterprises or small enterprises, they have made significant investment in R & D, so as to contribute innovative products to the market For our pharmaceutical enterprises, it also means that they can save the lives of patients and help the wounded We, the American Chamber of Commerce, are encouraged by the recent enforcement actions of the Chinese government on intellectual property protection We hope that these activities will continue We, the American Chamber of Commerce, sincerely hope to continue our cooperation with the Chinese government and the Chinese industry in the future Mark Elliott, executive director of the International Intellectual Property Center of the American Chamber of Commerce, delivered a speech Mr rod hunt, senior vice president of Pharma, said that today's theme is a very important one, which can promote our innovation Thank you very much to our colleagues for running this summit, which enables us to further cooperate Chris weibach, chairman of the board of directors of the American pharmaceutical research and Manufacturers Association (PhRMA), vice chairman of the European Federation of pharmaceutical industry associations and CEO of Sanofi Aventis, led the delegation to give a speech in which he spoke highly of China's pharmaceutical innovation ability and introduced the trend of pharmaceutical innovation and research in the world 'our industry is actually a strategic industry,' he said Innovation is a very important engine The environment we live in has brought many problems, pollution and chronic diseases In today's world, we must support and encourage R & D to benefit patients How to create an environment conducive to new drug research and development? I'm very glad that this conference chose the theme of intellectual property protection It takes a long time for new drug research and development to prove its effectiveness and safety Without intellectual property protection, innovation cannot be proved As chairman of PhRMA, I come to China every year This year, we talked about the issue of intellectual property rights, and we can cooperate in other areas in the future Chris weibach, chairman of the board of directors of PhRMA, vice chairman of the Federation of European pharmaceutical industry associations and CEO of Sanofi Aventis, addressed Bian Zhenjia, deputy director of the State Food and drug administration He said that the theme of the summit is "intellectual property protection and innovation and development of the pharmaceutical industry", which was chosen very well As we all know, the innovative invention of drugs has the characteristics of large investment, high risk, high difficulty, long cycle and wide market It is one of the most dependent technical fields for intellectual property protection, especially patent protection Mansfield, a famous American economist, once studied and analyzed that without patent protection, 60% of drug inventions could not be developed and 65% would not be utilized The protection of drug patent right is closely related to the administrative registration and approval of drug supervision and administration department If the drugs approved by the drug regulatory authorities involve other people's patents, the approval behavior will inevitably affect the rights and interests of drug patentees When we register and approve drugs, we also pay great attention to the problems related to drug patents We have been looking for relatively perfect solutions, trying to maximize the protection of the legitimate rights and interests of patent holders in the process of drug registration and approval In this regard, we are still in the stage of continuous improvement In recent years, the China Council for the promotion of drugs and the American pharmaceutical research and Manufacturers Association have done a lot of work, and we appreciate it Bian Zhenjia, deputy director of the State Food and drug administration, delivered a speech by Chen Xiaohong, Deputy Minister of health, and expressed warm congratulations on the opening of the summit on behalf of the Ministry of health He said that as we all know, the development of medical and health undertakings is related to the health of hundreds of millions of people and is a major livelihood issue For the healthy development of public health in any country, the pharmaceutical industry plays an important role in promoting It is an important part of building a drug supply guarantee system and a sound basic medical and health system to promote the independent innovation ability of pharmaceutical enterprises and the optimization and upgrading of the pharmaceutical industrial structure The Chinese government attaches great importance to the innovation of pharmaceutical science and technology and the development of related industries, which need a good intellectual property system and environment It is hoped that China and the United States can closely focus on global medical and health needs and work together to achieve greater and more benefits for the health and health cause of all mankind Chen Xiaohong, Vice Minister of health, delivered a speech at the conference venue Song Ruilin, executive chairman of China Pharmaceutical Association, presided over the opening ceremony Song Ruilin, executive chairman of China Pharmaceutical Association, said that since 2009, the China US pharmaceutical industry summit has been successfully held in China and the United States once, attracting the top 30 pharmaceutical companies in the world and the top 30 pharmaceutical companies in China A large number of entrepreneurs and executives from top 100 enterprises, innovative small and medium-sized pharmaceutical enterprises and first-class pharmaceutical research institutes participated in the event, and they were highly praised by the industry This year is the third China US pharmaceutical summit This summit is bound to have a significant and far-reaching impact on the pharmaceutical exchanges between China and the United States, promote mutual sharing, mutual benefit and achieve our common development goals (Information Department of China Pharmaceutical Association)